Prescient Therapeutics (ASX: PTX)
Live Investor Briefing
Thursday, 10th September at 10am (AEST)
Friday, 18th September at 11am (AEST)
Join to hear from Prescient Therapeutics CEO James McDonnell for an investor briefing.
In this session, James will discuss:
- Why PTX-100 one of the most advanced therapies on the ASX – now in Phase 2a trial.
- How 100% of evaluable CTCL patients saw a halt or reversal of their cancer in the previous Phase 1b study (a cancer that many clinicians see as a death sentence).
- How this technology is able to achieve such remarkable results, and why the company is approaching a potentially significant inflection point for investors.
PTX-100 is at an advanced stage in clinical trials and at the point where large pharmaceutical companies may begin to take a serious interest in de-risked assets like this. They have an opportunity to potentially become one of Australia’s biotech success stories.
This is a live and interactive online session, and participants are encouraged to ask questions. Spots are limited, so secure yours today.
Can’t make this time, register to receive the replay.
Attend The Session
By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.
FEATURED SPEAKER
James McDonnell
CEO
James McDonnell is a seasoned leader in the biopharmaceutical industry, bringing over 25 years of global experience in pharmaceuticals, with a particular focus on blood disorders and hematological malignancies such as Myeloma, Myelodysplasia, and CML.
Throughout his career, James has held senior leadership roles at renowned pharmaceutical companies, including Pharmion and CSL Vifor. At Pharmion, he spearheaded the growth of its oncology and hematology portfolio as Head of Global Marketing, contributing significantly to the company’s acquisition by Celgene Corporation for US$2.9 billion. Most recently, James served as Global Commercial Lead for Patient Blood Management at CSL Vifor, where he drove key enterprise-wide strategic initiatives.
James is a registered pharmacist and a member of the Royal College of Pharmacy. He holds a Graduate Diploma in Marketing from Monash University and is a graduate of the Australian Institute of Company Directors.
Reach Markets provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.
Reach Investment Group Nominees Pty Ltd, a related entity of Reach Markets, holds options in Prescient Therapeutics Limited.